Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
Conditions: Parathyroid Carcinoma; Primary Hyperparathyroidism Intervention: Drug: KHK7580 Sponsor: Kyowa Hakko Kirin Co., Ltd Recruiting - verified September 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hyperparathyroidism | Parathyroid Cancer | Research | Study